RAW 264.7 murine macrophages were exposed to the pyrrole-based compound 3,5-Dibromo-4-(3,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylic acid ethyl ester , which is a known microtubule depolymerizing agent with antitumor activity. 1, 2, 3, 4 In this study exposure to JG-03-14 reduced the production of pro-inflammatory molecules by macrophages activated with lipopolysaccharide (LPS). Treatment with the pyrrole-based compound decreased the concentration of tumor necrosis factor-α (TNF-α) and nitric oxide (NO) released from the macrophages. Exposure to JG-03-14 also decreased TNF-α mRNA expression levels and the protein expression levels of inducible nitric oxide synthase (iNOS), the enzyme responsible for NO production in the activated macrophages. Furthermore, JG-03-14 treatment significantly changed the degradation profile of IκB-β, an inhibitor of the NF-κB transcription factor, which suggests that JG-03-14 may attenuate the activation of the LPS-induced NF-κB signaling 2 pathway needed to produce the pro-inflammatory mediators. We conclude that JG-03-14 possesses anti-inflammatory properties.
Introduction
Studies of 3,5-Dibromo-4-(3,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylic acid ethyl ester (JG-03-14, Figure 1 ), a tetrasubstituted brominated pyrrole, have demonstrated that this compound possesses potent microtubule depolymerizing properties by binding tubulin at the colchicine site. 1,2,3 As a major component of the eukaryotic cytoskeleton, microtubules contribute to cell physiology by participating in chromosome segregation during mitosis, organelle trafficking and cell signaling events, and disruption of tubulin dynamics is the target of several anticancer drugs. Although colchicine was the first drug shown to bind tubulin, resulting in the loss of microtubules and the prevention of new microtubule formation, it is too toxic to be used in a clinical setting. 4, 5, 6 Therefore, less toxic compounds, such as JG-03-14, that bind at the colchicine site of tubulin have drawn considerable attention. Earlier studies that demonstrated the importance of the C-2 and C-4 positions of JG-03-14 for tubulin binding also showed that the tubulin-depolymerizing property of this compound correlated with anti-proliferative activity in a wide range of cancer cell lines. 2, 3 Further investigations demonstrated that JG-03-14 promotes autophagic cell death of tumor cells and that it is active against tumor cells expressing the multidrug resistance pump, providing additional support for the potential use of JG-03-14 to treat malignancies. 7, 8 However, little is known about the effect of JG-03-14 on immune cells, specifically macrophages, which detect invading microorganisms in the tissues, carry out phagocytosis, and produce pro-inflammatory mediators. 9 While acute inflammation is protective against infections and tissue injury, chronic inflammation may lead to inflammatory disorders and cancers. 10, 11, 12, 13, 14 Studies have shown that other pyrrole-containing compounds possess anti-inflammatory properties. 15, 16, 17 Therefore, in addition to understanding the microtubule depolymerizing properties of JG-03-14, investigating the effects of JG-03-14 on the proinflammatory activity of macrophages is important in order to expand our knowledge of the compound's bioactive properties and its clinical potential.
The Nuclear Factor-kappa B (NF-κB) transcription factor is one of the most important regulators of the inflammatory response. In macrophages, the pro-inflammatory NF-κB signaling pathway can be activated by lipopolysaccharide (LPS), a cell wall component of gram-negative bacteria, which binds to the Toll-like receptor 4 (TLR4) complex and triggers the production of pro-inflammatory molecules. 9 Initiation of this pathway involves a complex signaling architecture that ultimately phosphorylates and activates the IKK complex, which in turn phosphorylates the inhibitory proteins IκB-α and IκB-β that are bound to the NF-κB transcription factor. 18 These inhibitory proteins are then ubiquitinated and degraded in a cytosolic proteasome. 18 The now-active NF-κB translocates into the nucleus and promotes the (JG-03- 14) transcription of inflammatory response genes. In mice, some of these genes include TNFA, which encodes the cytokine tumor necrosis factor-α (TNF-α) and NOS2, which encodes inducible nitric oxide synthase (iNOS). The iNOS enzyme catalyzes the reaction of L-arginine to citrulline, which produces nitric oxide (NO) radicals as a byproduct, useful as both a vasodilator and an anti-pathogenic oxidant.
To assess the effects of JG-03-14 on the macrophage inflammatory response, our study investigated how exposure to JG-03-14 affected the production of NO, iNOS, and TNF-α by RAW 264.7 macrophages activated with LPS. We also investigated JG-03-14's effects on the relative mRNA expression of TNF-α as well as the degradation of the IκB-β inhibitory protein after LPS activation. We found that JG-03-14 suppressed the production of the inflammatory molecules and our data further suggest that this may be caused by an effect on the NF-κB signaling pathway.
Materials and methods

Cell Culture
RAW 264.7 macrophages were purchased from ATCC and plated in T75 filter-top flasks, where they were managed under sterile conditions and grown at 37°C with 5% CO2. Cells were maintained in RPMI complete medium containing 10% fetal calf serum and supplemented with 
Fluorescence Microscopy
Cells were plated on coverslips held in 6-well plates and allowed to adhere overnight. After 
Nitric Oxide Assay
Populations of 3.3 x 10 6 cells were incubated with LPS for 20 hours before being harvested for NO assessment. Nitrite accumulation in the supernatants was assessed using a standard Greiss assay. Briefly, an equal volume of supernatant (50 μL) was reacted with equal volumes of each Greiss reagent (50 μL each) and the absorbance was read at 550 nm using a BeckmanCoulter DTX 800 Multimode Detector.
Western Blotting
Populations of 3. Stripping Solution according to the manufacturer's instructions and re-probed using a mouse anti-actin antibody (Sigma-Aldrich) at a 1:5000 dilution using the previously described procedure.
TNF-α ELISA
Populations of 3.3 x 10 6 cells were treated as previously described. Supernatant samples collected from the cultures were diluted 1:100 then analyzed to quantify the presence of TNF-α using an OptEIA TM ELISA assay (BD Biosciences). Protocol was carried out according to the manufacturer's directions.
TNF-α qPCR
Populations of 3 x 10 5 cells were treated as previously described. RNA from these cultures was harvested using the Qiagen RNEasy Mini-Kit. After RNA was collected, cDNA was created using Origene's First-Strand cDNA Synthesis Kit following Origene's standard protocols and using a Bio-Rad DNAEngine thermo-cycler. The gene of interest was amplified using Origene primers (qSTAR qPCR primer pairs against Mus musculus Tnf and Actb) and Quanta
Biosciences B-R SYBR Green SuperMix for iQ in 20 μL reactions. Reaction progress was monitored using a Bio-Rad CFX Connect Real-Time System and its associated software. Cq data were analyzed using a normalized expression method (ΔΔCq).
IκB-β Densitometry and Analysis
Densitometry of IκB-β western blots was completed using a Kodak Gel Logic 200 imaging system and its associated software. Densities were normalized against the initial density of IκB-β on each blot. The relative density values were then linearized assuming exponential decay by taking the natural logarithm of the relative densities. The best-fit linear slope was then averaged between independent experimental replicates for comparison. Standard error was calculated from the variability of this slope between replicates but not the variability from the fit of the individual data sets to a linear trend. The minimum relative densities were also averaged between independent experimental replicates for comparison, and once again standard error was calculated from the variability of these relative density minima.
Statistics
for IκB-β densitometry data, which utilized heteroscedastic two-tailed t-tests for comparison of the means.
Results
Microtubule network
The microtubule-depolymerizing effects of JG-03-14 were confirmed using fluorescence microscopy of RAW 264.7 cells treated with JG-03-14 with and without subsequent LPS activation ( Figure 2 ). Qualitative assessment showed that resident macrophages demonstrated consistent, diffuse distribution of microtubules, while activation of these macrophages with LPS increased microtubule organizing center (MTOC) brightness and microtubule network complexity. This is consistent with previous studies. 19, 20 When pretreated with JG-03-14, the cells failed to construct a diffuse microtubule network as seen in the resident macrophages, however, LPS activation still increased MTOC brightness despite the lack of a clear microtubule network.
Cell viability
Next, RAW 264.7 cells in culture were assessed for viability across a range of JG-03-14
concentrations over a 21-hour incubation period. A slight decrease in cell viability was detected after exposure to concentrations up to eight times those used in this study ( Figure 3 ). 
Production of pro-inflammatory molecules
In order to assess the effects of JG-03-14 on the inflammatory response, we analyzed NO production by LPS-activated RAW 264.7 cells with and without JG-03-14 pretreatment using a standard Greiss assay. We found that NO production was significantly reduced in cells pretreated for one hour with 0.5 μM JG-03-14 and activated with 500 ng/mL LPS (Figure 4a ).
Corresponding iNOS levels within the lysates from the same cells were also examined using western blot analysis, and results correlated with NO levels (Figure 4b ). We also measured TNF-α released from the macrophages using an ELISA and found the amount of secreted TNF-α to be significantly reduced in cells pretreated with either 0.25 or 0.5 μM JG-03-14 ( Figure 5a ). We then used qPCR to compare the relative TNFA expression levels between activated macrophages exposed to JG-03-14 and those that were not. Relative expression levels of TNFA mRNA were found to be decreased in cultures pretreated with either 0.25 or 0.5 μM JG-03-14 ( Figure 5b) . 
NF-κB activation
We hypothesized that the attenuation of iNOS and TNF-α protein expression may be due to an effect that JG-03-14 has on the activation of the NF-κB transcription factor. To assess the effect of the compound on the NF-κB activation in RAW 264.7 macrophages, we tracked the relative amounts of IκB-β over time within the macrophages using western blot analysis. Our results show that pretreatment with JG-03-14 significantly altered the degradation profile of IκB-β within activated RAW 264.7 macrophages (Figure 6a and 6b) . Densitometry of the bands representing IκB-β protein relative to the band at t = 0 was used to quantify and analyze the effect of JG-03-14 on the degradation of IκB-β (Figure 6c) . In order to assess differences in the IκB-β degradation rate between the cells pretreated with 0.5 μM JG-03-14 and those that were not, the densitometry data were linearized assuming exponential decay and a best-fit linear slope was found for each of the resultant data. The magnitude of the slope was found to be significantly decreased when analyzed from cells pretreated with 0.5 μM JG-03-14 (figure 7a), indicating that the rate of decay of the steady state amount of IκB-β within the cells after LPS activation was also decreased. Furthermore, the minimum density band on each blot was found and averaged between independent experiments. The minimum IκB-β level in the activated cells during the first two hours after LPS activation was found to be increased by about 20% in cells pretreated for one hour with 0.5 μM JG-03-14 (Figure 7b) , indicating that the minimum steadystate amount of IκB-β in the cells was significantly greater in the cells pretreated with JG-03-14.
These results, taken together with the observed decrease in production of inflammatory molecules by activated macrophages, suggest that exposure to JG-03-14 may be suppressing NF-κB's ability to promote pro-inflammatory gene transcription in response to LPS stimulation. (B) Minimum IκB-β band densities relative to the t = 0 band density in the corresponding data set for each treatment were compared. In each comparison, means were calculated from data collected from three independent experiments, and compared using a heteroscedastic two-tailed ttest. **p<0.01, ***p<0.001.
Discussion
Previous studies have shown that JG-03-14 possesses potent microtubule depolymerizing and anti-tumor activity, lending support to the compound's potential as a cancer chemotherapeutic properties, adding support to other studies demonstrating the anti-inflammatory properties of pyrrole compounds. 15, 16, 17 The change in the IκB-β degradation profile due to pretreatment with JG-03-14 could have multiple independent or inter-related causes. The study we conducted showed the change in the steady-state amount of IκB-β over time after macrophage activation, which can be affected both by the kinetics of IκB-β degradation and resynthesis of the protein. It is also known that newly synthesized IκB-β in a hypophosphorylated form can bind to NF-κB in the nucleus without inhibiting NF-κB's ability to bind to DNA and promote gene transcription. 21 Our technique did not discriminate between IκB-β with and without post-translational modifications.
Therefore, there are several ways that JG-03-14 may be mediating the observed antiinflammatory effect. While it is possible that the destabilization of microtubules by JG-03-14 could be disrupting vesicle trafficking resulting in a reduction in TNF-α secreted by the macrophages, our results also suggest that this compound may directly affect the components of the LPS-induced NF-κB pathway, or possibly alter the events leading to the degradation of IκB-β. Another intriguing possibility is that JG-03-14's effect on NF-κB activation is a consequence of its anti-microtubule activity, which would suggest a connection between the microtubule network and the LPS-induced NF-κB pathway. Recent studies showing a connection between cytoskeletal proteins and the activation and/or kinetics of the NF-κB pathway make this possibility an important foundation for future inquiry. 22 Furthermore, a study published in 1992
reported that the compound taxol, a potent microtubule stabilizer, exerted LPS-like effects upon macrophages by inducing the mRNA expression of TNF-α and interleukin-1β in the absence of LPS. 23 The fact that a microtubule stabilizer induced the expression of pro-inflammatory products in that study and a microtubule destabilizer repressed pro-inflammatory products in the present one may be a coincidence, but it warrants further investigation. These future studies may reveal a novel interaction between microtubules and the signaling components responsible for the activation of NF-κB.
If JG-03-14 is instead found to have a direct interaction with the signaling components of the NF-κB pathway, it may increase its potential as an anti-tumor agent. Indeed, many cancers are exacerbated by a constitutively active NF-κB transcription factor, which can be caused by various perturbations or mutations in the normal pathway and its signaling termination programs. 13, 24 A compound that has anti-tumor properties while also debasing a cancer cell's resistance to chemotherapeutics may have clinical attractiveness for treating more aggressive cancers. Besides elucidating the targets of JG-03-14, it would also be prudent to test JG-03-14's anti-tumor efficacy on aggressive cancer types known to contain aberrations in their NF-κB signaling machinery.
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